A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.

What Was Tested

Researchers studied Copper (Supplement) in the context of pcos in this observational study publication.

Previous evidence indicates that combining myo-inositol and D-chiro-inositol in a specific 3.6:1 ratio may support ovarian physiology and reproductive performance in women with PCOS.

Who Took Part

According to the abstract, 92 women were involved.

PubMed indexes the participants as adults, women only.

A retrospective observational cohort study was conducted, including 92 women diagnosed with PCOS according to the Rotterdam criteria.

Patients were allocated to 2 groups: those who used the MYO:DCI 3.6:1 antioxidant-containing supplement (Group 1) and those who followed conventional supplementation (Group 2).

How the Study Was Run

The researchers set it up as a pilot study.

It is described as a pilot, a small early test of whether a larger Copper (Supplement) study would be practical.

Outcomes assessed included ovarian response, fertilization rates, blastocyst development and pregnancy results.

What Was Measured

PubMed files the paper under topics including Inositol, Antioxidants, Pilot Projects, Polycystic Ovary Syndrome, Dietary Supplements, Fertilization in Vitro and Infertility, Female.

The authors tagged it with the keywords In vitro fertilization (IVF), MYO:DCI ratio and polycystic ovary syndrome (PCOS).

What This Means in Plain Language

The paper is a pilot study of Copper (Supplement) in 92 women in people with pcos.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology), a journal based in England.

More context: the Copper (Supplement) compound page, PCOS research.